Lupin announced the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 50 mg of Astellas Pharma Global Development, Inc.
Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of USD 1,600 million in the U.S. (IQVIA MAT July 2024).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
